All In MedTech

Device Trial Radar · NCT04915924

Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea

Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea (Korea HM3 PMS)

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

358

Actual

Start

Oct 30, 2020

Primary completion

Jun 2, 2024

Study completion Jun 2, 2024

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
First posted
Jun 7, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Korea HM3 PMS is a prospective, single arm, open-label, multi-center, post market surveillance is designed to evaluate clinical and functional outcomes with the HM3 LVAS as a treatment for advanced heart failure. The PMS will enroll up to 300 patients, that meet the Health Insurance Review and Assessment (HIRA) guidelines for LVAD implantation, from up to 25 sites in South Korea. Subjects who will be implanted but not included in the PMS can be enrolled retrospectively after obtaining their informed consent. The surveillance period for this PMS is expected to be 4 years from the time of HM3 approval in Korea, concluding on June 2, 2024.

Conditions

  • Advanced Heart Failure

Interventions

  • HeartMate 3™ left ventricular assist system (HM3 LVAS)Device

    Advanced heart failure patients will be implanted with the HM3 LVAS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Efficacy Endpoint: Kaplan-Meier Success Rate of Overall Survival to Transplant, Myocardial Recovery or on Device Support Free of Debilitating Stroke (60 Days Post-stroke Modified Rankin Score >3) or Reoperation for Pump ReplacementTime frame: From enrollment to 36 months
  2. Primary Safety Endpoint: Number of Cumulative Occurrences of Adverse EventsTime frame: From enrollment until the study conclusion date (up to 43 months, 3 days)

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Korea University Ansan Hospital

    Ansan, South Korea

  • Sejong Hospital

    Bucheon-si, South Korea

  • Pusan National University Hospital

    Busan, South Korea

19 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.